Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

NCT00200512
completedphase_3

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

NCT00200525
completedphase_3

A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

NCT00145171
completedphase_3

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

NCT00142545

Clinical Trials (4)

Showing 4 of 4 trials
NCT00200512Phase 2

Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months

Completed
NCT00200525Phase 3

Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease

Completed
NCT00145171Phase 3

A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.

Completed
NCT00142545Phase 3

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4